Cargando…

Myelofibrosis and Survival Prognostic Models: A Journey between Past and Future

Among the myeloproliferative diseases, myelofibrosis is a widely heterogeneous entity characterized by a highly variable prognosis. In this context, several prognostic models have been proposed to categorize these patients appropriately. Identifying who deserves more invasive treatments, such as bon...

Descripción completa

Detalles Bibliográficos
Autores principales:	Duminuco, Andrea, Nardo, Antonella, Giuffrida, Gaetano, Leotta, Salvatore, Markovic, Uros, Giallongo, Cesarina, Tibullo, Daniele, Romano, Alessandra, Di Raimondo, Francesco, Palumbo, Giuseppe A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10053868/ https://www.ncbi.nlm.nih.gov/pubmed/36983189 http://dx.doi.org/10.3390/jcm12062188

Ejemplares similares

Ruxolitinib treatment in myelofibrosis and polycythemia vera causes suboptimal humoral immune response following standard and booster vaccination with BNT162b2 mRNA COVID-19 vaccine
por: Palumbo, Giuseppe A., et al.
Publicado: (2023)

Prediction of Survival and Prognosis Migration from Gold-Standard Scores in Myelofibrosis Patients Treated with Ruxolitinib Applying the RR6 Prognostic Model in a Monocentric Real-Life Setting
por: Duminuco, Andrea, et al.
Publicado: (2022)

Clinical outcome of SARS-CoV-2 infections occurring in multiple myeloma patients after vaccination and prophylaxis with tixagevimab/cilgavimab
por: Duminuco, Andrea, et al.
Publicado: (2023)

Mesenchymal stromal cells in tumor microenvironment remodeling of BCR-ABL negative myeloproliferative diseases
por: La Spina, Enrico, et al.
Publicado: (2023)

Immunoproteasome Genes Are Modulated in CD34(+) JAK2(V617F) Mutated Cells from Primary Myelofibrosis Patients
por: Di Rosa, Michelino, et al.
Publicado: (2020)

Focus on Osteosclerotic Progression in Primary Myelofibrosis
por: Spampinato, Mariarita, et al.
Publicado: (2021)

PB2534: SARS-COV-2 IMMUNIZATION AFTER VACCINES IN PATIENTS WITH HEMOGLOBINOPATHY: A SINGLE CENTER EXPERIENCE
por: Duminuco, Andrea, et al.
Publicado: (2023)

AIPSS‐MF machine learning prognostic score validation in a cohort of myelofibrosis patients treated with ruxolitinib
por: Duminuco, Andrea, et al.
Publicado: (2023)

P1047: AIPSS-MF MACHINE LEARNING MODEL AS USEFUL PROGNOSTIC SCORE COMPARED TO IPSS IN THE SETTING OF MYELOFIBROSIS PATIENTS TREATED WITH RUXOLITINIB
por: Duminuco, Andrea, et al.
Publicado: (2023)

Plasticity of High-Density Neutrophils in Multiple Myeloma is Associated with Increased Autophagy Via STAT3
por: Puglisi, Fabrizio, et al.
Publicado: (2019)

P855: FERROPTOSIS AS A NEW BCMA-TARGETED IMMUNOTHERAPY OFF-TARGET EFFECT IN MULTIPLE MYELOMA
por: La Spina, Enrico, et al.
Publicado: (2023)

P59 ACTIVE TREATMENT AND LOW IGM ARE ASSOCIATED WITH INFERIOR SARS-COV-2 SPIKE ANTIBODY RESPONSE TO THREE DOSES OF COVID-19 RNA VACCINATION IN PATIENTS WITH MULTIPLE MYELOMA
por: Duminuco, A., et al.
Publicado: (2023)

Proteomic Analysis Reveals Autophagy as Pro-Survival Pathway Elicited by Long-Term Exposure with 5-Azacitidine in High-Risk Myelodysplasia
por: Romano, Alessandra, et al.
Publicado: (2017)

P988: LACTATE RESHAPES TUMOR MICROENVIRONMENT AND METABOLIC PROFILE IN MYELOFIBROSIS
por: Giallongo, S., et al.
Publicado: (2022)

Heme oxygenase-1 nuclear translocation regulates bortezomib-induced cytotoxicity and mediates genomic instability in myeloma cells
por: Tibullo, Daniele, et al.
Publicado: (2016)

Myeloid Derived Suppressor Cells (MDSCs) Are Increased and Exert Immunosuppressive Activity Together with Polymorphonuclear Leukocytes (PMNs) in Chronic Myeloid Leukemia Patients
por: Giallongo, Cesarina, et al.
Publicado: (2014)

Mitochondrial Bioenergetics at the Onset of Drug Resistance in Hematological Malignancies: An Overview
por: Barbato, Alessandro, et al.
Publicado: (2020)

IGFBP-6/sonic hedgehog/TLR4 signalling axis drives bone marrow fibrotic transformation in primary myelofibrosis
por: Longhitano, Lucia, et al.
Publicado: (2021)

Acquired hemophilia A following COVID-19 vaccination – The importance of prompt diagnosis: A case report
por: Duminuco, Andrea, et al.
Publicado: (2022)

P1558: PROPHYLAXIS WITH TIXAGEVIMAB-CILGAVIMAB IN SINGLE-CENTER EXPERIENCE CAN REDUCE SEVERE COMPLICATIONS RELATED TO SARS-COV-2 INFECTION IN HEMATOLOGICAL PATIENTS
por: Duminuco, Andrea, et al.
Publicado: (2023)

Monocytic Myeloid Derived Suppressor Cells in Hematological Malignancies
por: Palumbo, Giuseppe Alberto, et al.
Publicado: (2019)

Clinical Benefit of Long-Term Disease Control with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients
por: Parisi, Marina Silvia, et al.
Publicado: (2019)

Serum free light chains and multiple myeloma: Is it time to extend their application?
por: Markovic, Uros, et al.
Publicado: (2020)

Granulocyte-like myeloid derived suppressor cells (G-MDSC) are increased in multiple myeloma and are driven by dysfunctional mesenchymal stem cells (MSC)
por: Giallongo, Cesarina, et al.
Publicado: (2016)

IGFBP-6: At the Crossroads of Immunity, Tissue Repair and Fibrosis
por: Liso, Arcangelo, et al.
Publicado: (2022)

Mesenchymal Stem Cells (MSC) Regulate Activation of Granulocyte-Like Myeloid Derived Suppressor Cells (G-MDSC) in Chronic Myeloid Leukemia Patients
por: Giallongo, Cesarina, et al.
Publicado: (2016)

Monocytic myeloid‐derived suppressor cells as prognostic factor in chronic myeloid leukaemia patients treated with dasatinib
por: Giallongo, Cesarina, et al.
Publicado: (2017)

SPARC expression in CML is associated to imatinib treatment and to inhibition of leukemia cell proliferation
por: Giallongo, Cesarina, et al.
Publicado: (2013)

Bortezomib modulates CHIT1 and YKL40 in monocyte-derived osteoclast and in myeloma cells
por: Tibullo, Daniele, et al.
Publicado: (2015)

The Role of Inflammation and Inflammasome in Myeloproliferative Disease
por: Longhitano, Lucia, et al.
Publicado: (2020)

Potential clinical impact of T-cell lymphocyte kinetics monitoring in patients with B cell precursors acute lymphoblastic leukemia treated with blinatumomab: a single-center experience
por: Duminuco, Andrea, et al.
Publicado: (2023)

TLR4 Signaling and Heme Oxygenase-1/Carbon Monoxide Pathway Crosstalk Induces Resiliency of Myeloma Plasma Cells to Bortezomib Treatment
por: Scandura, Grazia, et al.
Publicado: (2022)

Relapse of immune-mediated thrombotic thrombocytopenic purpura following mRNA COVID-19 vaccination: a prospective cohort study
por: Giuffrida, Gaetano, et al.
Publicado: (2022)

A Real-Life Survey of Venous Thromboembolic Events Occurring in Myeloma Patients Treated in Third Line with Second-Generation Novel Agents
por: Calafiore, Valeria, et al.
Publicado: (2020)

TLR4 signaling drives mesenchymal stromal cells commitment to promote tumor microenvironment transformation in multiple myeloma
por: Giallongo, Cesarina, et al.
Publicado: (2019)

Lenalidomide plus Dexamethasone Combination as First-Line Oral Therapy of Multiple Myeloma Patients: A Unicentric Real-Life Study
por: Del Fabro, Vittorio, et al.
Publicado: (2023)

Lactate trafficking inhibition restores sensitivity to proteasome inhibitors and orchestrates immuno‐microenvironment in multiple myeloma
por: Barbato, Alessandro, et al.
Publicado: (2023)

Ixazomib Improves Bone Remodeling and Counteracts Sonic Hedgehog Signaling Inhibition Mediated by Myeloma Cells
por: Tibullo, Daniele, et al.
Publicado: (2020)

My Journey: Past, Present, Future
por: Earat, Ramanan
Publicado: (2022)

Proteasome Inhibitors as a Possible Therapy for SARS-CoV-2
por: Longhitano, Lucia, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_hd15jo03ig33tf7jvujuugnjq1